CET Time zone (UTC +1)
THE PROGRAMME WILL BE AVAILABLE SOON.
YOU CAN CONSULT THE 2025 EDITION BELOW.
Exploring Sarcopenia and Cachexia: Multidisciplinary Perspectives
Welcome to the first day of our Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders. Discover world-renowned experts to discuss the latest research and advancements in the field.
08:30 – 09:30
HALL A
BASIC SCIENCE
Session 1
Epigenetics of sarcopenia and cachexia
Chairs: Brittany Counts, USA – TBC
Abnormal DNA methylation and altered transcriptome in muscle five years after critical illness
Ilse Vanhorebeek, Belgium
Skeletal muscle methylome-transcriptome disruptions during the onset and progression of colorectal cancer-induced cachexia
Nicholas Greene, USA
Disrupted methionine cycle triggers muscle atrophy in cancer cachexia through epigenetic regulation of REDD1
TBC
Epigenetics of cancer cachexia
TBC
Discussion
HALL B
BASIC SCIENCE
Session 2
Kidney, kidney cancer, and cachexia
Chairs: TBN
Cachexia as multi-organ disease
Marilia Seelaender, Brazil
Tracing Early Oncogenic Events in Renal Cancer: Implications for Cachexia and HIF Signaling
Joanna Lima, Brazil
HIF-2α–driven paraneoplastic syndromes in aggressive kidney cancer: linking PTHrP, hypercalcemia, and cachexia
James Brugarolas, USA
Tumor suppressor pathways in renal cell carcinoma: links to systemic metabolism, cachexia and obesity
TBC
Discussion
09:40 – 10:40
HALL A
BASIC SCIENCE
Session 3
Loss of protein quality control in muscle aging and disease
Chairs: Denis Guttridge, USA – TBN
Protein degradation in disease – insights from human biopsies
Volker Adams, Germany
Protein aggregation in muscle disease and aging
Benjamin Miller, USA
Integrated stress response in protein quality control in muscle
Tracy Anthony, USA
Insolubilome in muscle aging
Fabio Demontis, USA
Discussion
HALL B
BASIC SCIENCE
Session 4
Neuromuscular impairments in cachexia and sarcopenia
Chairs: Andrea Bonetto, USA – TBN
Impaired motor unit connectivity in cancer
Joshua Huot, USA
New insights on neuromuscular junction instability with inactivity
Marco Narici, Italy
Cancer-induced NMJ disruption
TBC
NMJ disruption and mitochondria dysfunction trigger muscle atrophy
TBN
Discussion
10:50-11:50
HALL A
TBN
Session 5
Connecting geroscience and osteosarcopenia
Chairs: Marco Brotto, USA – Fabrizio Pin, USA
The role of the ribosomes in muscle and bone health
TBN
Targeting optimal recovery in fragility fracture patients with co-existing osteosarcopenia
Ronald Man Yeung Wong, Hong Kong
Tryptophan metabolites as regulators of bone and muscle health
Gustavo Duque, Canada
Stem cell exhaustion in osteosarcopenia
TBC
Discussion
HALL B
BASIC SCIENCE
Session 6
Systems biology of cachexia
Chairs: Mauricio Berriel Diaz, Germany – Erin Talbert, USA
Cross-study meta-analysis of the cancer cachexia transcriptome
Yoshiaki Tanaka, Canada
Functional interrogation of the pancreatic cancer cachexia secretome
Min Deng, Norway
Metabolite-mediated epigenetic changes in immune cells induce a coordinated response across tissues in cachexia
TBN
The gut microbiome and cancer cachexia
Laure Bindels, Belgium
Discussion
Break
12:00 – 12:50
Lunch Break
Opening Session
13:00 – 14:00
Hall a
Session 7
Opening Session
Chairs: Teresa Zimmers, USA – Stefan Anker, Germany
Welcome
TBN
“Prometheus” basic science key note lecture: Cachexia and the immune tumor macroenvironment
Denis Guttridge, USA
“Hippocrates” clinical science key note lecture: Cancer and cachexia: an oncologist’s perspective
Jeffrey Crawford, USA
JCSM Update
TBC
14:15 – 15:30
HALL A
SARCOPENIA - CLINICAL
Session 8
Multi-organ wasting during incretin treatment
Chairs: Andrew Coats, Australia – Javed Butler, USA – David Glass, USA
Sex-dependent decreases in organ weight with GLP-1RA
Katsu Funai, USA
Liver, heart and bone during incretin treatment
Henning Langer, Germany
Do incretin mimetics cause cardiac atrophy?
Markus Anker, Germany
How does weight cycling affect different tissue compartments?
TBN
Can high protein diet prevent muscle wasting?
Maurizio Muscaritoli, Italy
Discussion
HALL B
TRANSLATIONAL
Session 9
Biology, bulk, and function. What is the intersection in cancer cachexia?
Chairs: Jose Garcia, USA
How neural and physiologic mechanisms integrate to dictate muscle function: translational examples
Richard L. Lieber, USA
Distinguishing functional decline and recovery: preclinical and clinical lessons in cachexia
Ishan Roy, USA
Muscle mass is not enough: distinct roles for muscle quality and mass in function
William Evans, USA
Muscle remodeling in cachexia: mechanisms linking cellular biology to contractile function
Brittany Counts, USA
Discussion
Break
15:30 – 16:30
WEST END & THOMAS ROOMS
POSTER SESSION
Poster Viewing 1
Poster session 1.1 Muscle Wasting & Sarcopenia
Posters 4-25 to 4-36
Chairs: Monty Montano, Stephan von Haehling
Poster session 1.2 Cachexia – animal models
Posters 2-01 to 2-12
Chairs: Xiling Shen, Jochen Springer
Poster session 1.3 Cancer Cachexia
Posters 3-13 to 3-21
Chairs: Mauricio Berriel Diaz, Paola Costelli
Poster session 1.4 Muscle Wasting & Sarcopenia
Posters 4-37 to 4-48
Chairs: Guilherme Fonseca, Joerg Schefold
Poster session 1.5 Nutrition & appetite
Posters 5-01 to 5-10
Chairs: Alessandro Laviano, Paula Ravasco
METROPOLITAN BALLROOM
ABSTRACT SESSION
Rapid Fire Abstracts Session 1
Chairs: Elke Dworatzek, Germany – Katja Gehmlich, UK
Accelerometer-determined physical activity and sarcopenic obesity risk in older European men and women (3-29)
Andreas Nilsson, Sweden
Localized chemotherapy drives tumor regression and halts cancer-associated cachexia (3-05)
Franciska Telebar, Vito Telebar-Žbulj, Austria
Impaired cAMP/PKA/CREB1 signaling drives mitochondrial dysfunction in skeletal muscle in cancer cachexia (3-11)
Andrea Graziani, Italy
Effects of multicomponent interventions on physical function for people with cancer cachexia (3-12)
Megan Bowers, UK
An assessment of the healthcare resource use and cost impacts of cachexia among cancer patients in the United States: a Medicare claims study (3-28)
Joshua Roth, USA
Local TGF-β signaling causes impaired contractability and low-response to exercise in human skeletal muscle (4-18)
Simon Dreher, Germany
Myofiber aryl hydrocarbon receptor is essential for maintaining skeletal muscle integrity (4-19)
Charlotte Claeyssen, Norway
Unravelling metabolic dysregulation in heart failure with frailty: insights from plasma metabolomics (4-87)
Konstantinos Prokopidis, UK
Ultrasound assessment of quadriceps muscle architecture as a diagnostic and prognostic tool in hospitalized older adults with sarcopenia (4-49)
Zahira Zohari, Malaysia
Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-07258669, a small-molecule MC4R antagonist: Results from first-in-human Phase 1 studies (8-08)
John D. Groarke, USA
16:30 – 17:45
HALL A
TBC
Session 10
Mitochondrial dysfunction as a therapeutic target in cachexia: exploring disease-specific mechanisms and shared pathways
Chairs: Volker Adams, Germany – Scott Bowen, UK
Tumor-driven mitochondrial dysfunction in cancer cachexia
Paola Costelli, Italy
Mitochondrial dysfunction in age associated cachexia
Russell Hepple, USA
Mitochondrial function as therapeutic target in cachexia
Beatrice Vahle, Germany
Novel pharmacological approaches to target mitochondria
Tienush Rassaf, Germany
Discussion
HALL B
CLINICAL
Session 11
Muscle disorders in acute medical care
Chairs: Wolfram Doehner, Germany – TBN
Muscular disease in the acute medical care setting – update 2026
Joerg C. Schefold, Switzerland
Frailty and lessons learnt from the SARS-CoV-2 pandemic
TBN
Progress in understanding neuromuscular disease in the ICU
TBN
Suggested clinical approaches to acute muscle wasting in the critically ill
Stefan Schaller, Austria
Discussion
Sponsored Symposium
17:50 – 18:35
Muscle wasting and cachexia: new multidisciplinary approach
Moderators: Stefan Anker, Germany – Andrew Coats, Australia – Ashol K. Vaid, India
An innovative approach to cancer cachexia: role of S-pindolol
Andrew Coats (Australia)
GLP1 therapy in obesity and loss of skeletal muscle: a new therapeutic target ?
Markus Anker, Germany
Amyotrophic lateral sclerosis (ALS) and muscle wasting: what can s-oxprenolol do about it ?
Jochen Springer (Germany)
Panel discussion
(Symposium supported by Actimed Therapeutics)
Reception
18:45 – 19:45
Welcome reception – Joint poster viewing
Register Now!
Embrace this opportunity to redefine the field and create lasting impact in the lives of patients worldwide.
Day 2: Friday, 11 December 2026
Comprehensive Exploration of Cancer Cachexia and Aging-Related Sarcopenia
Discover the second day of our programme, dedicated to exploring the complexities of cancer cachexia and aging-related sarcopenia. With a stellar lineup of international experts presenting their latest research and engaging in insightful panel discussions
CAREER CAFÉ
07:00 (TBC)
Ken Fearon Career Café – Meet the Mentor
(attendance upon application and confirmation)
08:30 – 09:30
HALL A
TRANSLATIONAL
Session 12
Cachexia in critical illness
Chairs: Stefan Schaller, Germany – TBN
Cachexia in CKD and AKI
Kamyar Kalantar-Zadeh, USA
Cachexia in T2DM – update 2026
TBN
Cachexia in sepsis
TBC
Cachexia induced by liver growth and injury
Leonidas Koniaris, USA
Discussion
HALL B
CLINICAL
Session 13
COACH-ED: crosstalks on diagnosing and treating cancer cachexia
Chairs: Maurizio Muscaritoli, Italy – TBC
Diagnosing and managing cachexia in the oncology and palliative care setting
TBC
Nutritional interventions in multimodal management of cancer cachexia
TBC
Clinical trials and innovation in cancer cachexia care
TBC
COACH-ED: program outcomes and future directions – the road ahead
Jose Garcia, USA
Discussion
Break
09:30 – 10:30
WEST END & THOMAS ROOMS
POSTER SESSION
Poster Viewing 2
Poster session 2.1 Therapeutic Development (pre-clinical)
Posters 7-01 to 7-12
Chairs: James Carson, Mitja Lainscak
Poster session 2.2 Muscle Wasting & Sarcopenia
Posters 4-80 to 4-90
Chairs: Gustavo Duque, Andreas Fischer
Poster session 2.3 Physical Activity & Training
Posters 6-01 to 6-13
Chairs: Volker Adams, Andrew Judge
Poster session 2.4 Muscle Wasting & Sarcopenia
Posters 4-01 to 4-12
Chairs: Philip Atherton, Henning Langer
METROPOLITAN BALLROOM
ABSTRACT SESSION
Rapid Fire Abstracts Session 2
Chairs: Wenwei Hu, USA – Jaap Keijer, The Netherlands
Role of growth hormone resistance in IGF-I deficient sarcopenic patients (4-44)
Michael Drey, Germany
Low relative muscle power in patients on haemodialysis: poor health outcomes of the SARC-HD (4-56)
Maryanne Zilli Canedo Silva, Brazil
Trajectories of skeletal muscle index in patients with endometrial cancer after surgery: A group-based trajectory modeling analysis (4-66)
Kiriko Abe, Japan
DNA methylation as a driver of long-term muscle transcriptome alterations in critical illness survivors (4-71)
Ceren Uzun, Belgium
The burden of malnutrition in patients with chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF): a systematic literature review (5-06)
Reshma Merchant, Singapore
The anti-inflammatory effects and safety of omega-3 fatty acids regarding dose, active ingredients, ratio and source in patients receiving haemodialysis: a systematic review and meta-analysis (5-01)
Joanne Reid, UK
Risk of sarcopenia in people with long-term conditions and multimorbidity: a prospective UK Biobank study (4-36)
Marion Guerrero Wyss, UK
Single-cell transcriptomics reveals cellular drivers of human skeletal muscle regeneration: implications for sarcopenia (4-27)
Joshua Price, UK
The impact of EWGSOP2-defined sarcopenia on treatment tolerance and survival in patients with lung cancer – preliminary data from a prospective cohort study (4-63)
Gunn Ammitzbøll, Denmark
Mitochondrial protein modulation as a therapeutic approach to counteract muscle wasting in cancer cachexia, steroid use, and disuse conditions (4-70)
Ibotombi Singh Sinam, Republic of Korea
10:30 – 11:30
HALL A
MEET THE EDITOR
Session 14
Novel insights into muscle atrophy and hypertrophy mechanisms
Chairs: Andrea Bonetto, USA – Denis Guttridge, USA
Do hypertrophying muscles reprogram their metabolism like cancer cells?
Henning Wackerhage, Germany
Tumor-derived ADAMTSL4 drives muscle atrophy and fibrosis in cancer cachexia
Mauricio Berriel Diaz, Germany
Integration of single nucleus multi-omics with spatial transcriptomics identifies the molecular signature of muscle wasting in cancer cachexia
Marco Sandri, Italy
The role of skeletal muscle fibrosis in cancer cachexia
Andrew R. Judge, USA
Discussion
HALL B
TRANSLATIONAL/CACHEXIA
Session 15
Biomarkers and mechanisms in cancer cachexia
Chairs: TBN
JAK1/2 inhibition delays cachexia and improves survival through increased food intake
Marcus Goncalves, USA
Responder analysis in the PACTO trial
Teresa Zimmers, USA
Unmasking complement: a causal pathway in cancer-induced muscle loss
Andrew Judge, USA
Plasma Hsp90 Level correlates with cachexia and shorter survival in cancer patients
Yi-Ping Li, USA
Discussion
11:45 – 13:00
HALL A
TBC
Session 16
Cancer cachexia emerging therapies
Chairs: TBC
Relevant endpoints for clinical trials in cancer cachexia
Stefan Anker, Germany
MC3/MC4R inhibition for cachexia
TBC
GDF15 inhibition to reduce cachexia and promote anti-tumor therapy
Eric Roeland, USA
s-pindolol
Andrew Coats, Australia
Discussion
HALL B
CLINICAL
Session 17
Cachexia in chronic illness: update 2026
Chairs: TBC
Stroke
Wolfram Doehner, Germany
Cachexia in heart failure – still an issue
TBC
COPD
Neil Greening, UK
Cachexia in MASH / MASLD
TBC
Discussion
Break
13:10 – 14:10
Lunch Break
Sponsored symposium
13:10 – 14:10
Defining meaningful endpoints in cancer cachexia:
a patient-to-regulatory perspective
Moderator: Richard Dunne, University of Rochester, USA
Panel discussants: Carole Motycka, Fight CRC, USA – Abigail Newell, Cancer Support Community, USA – Susan Martin, Research Triangle Institute, USA
(Symposium supported by Pfizer)
14:15 – 15:30
HALL A
GENERAL CACHEXIA - CLINICAL
Session 18
Pediatric cancer cachexia
Chairs: Erin Talbert, USA – Paola Costelli, Italy
Biomarkers of the systemic response to cancer in children
Daniel Runco, USA
Postnatal neuromuscular growth and the consequences of pediatric cancer therapies
Joe Chakkalakal, USA
Mechanisms of pediatric cancer cachexia
TBN
Pediatric CHOP chemotherapy acutely disrupts satellite-cell dynamics and blunts muscle mass in a sex-specific manner
Michael Wiggs, USA
The surgeon’s view
TBC
Discussion
HALL B
TRANSLATIONAL
Session 19
Defining cachexia, sarcopenia, and frailty
Chairs: Reshma Merchant, Singapore – Gustavo Duque, Canada
The conceptual and operational definition of sarcopenia
Ben Kirk, Australia
Measuring muscle quantity and quality, the options: DEXA, CT, MRI
Lars Johansson, Sweden
Secondary sarcopenia in chronic disease: when muscle loss is not just ageing
Stephan von Haehling, Germany
From sarcopenia to frailty and cachexia: clinical phenotypes, overlap, and outcomes
Paul Coen, USA
Sarcopenic obesity in CKD: a difficult entity
Angela Wang, Singapore
Discussion
Coffee Break
15:30 – 16:30
WEST END & THOMAS ROOMS
POSTER SESSION
Poster Viewing 3
Poster session 3.1 Muscle Wasting & Sarcopenia
Posters 4-49 to 4-60
Chairs: Guglielmo Sorci, Florian Strasser
Poster session 3.2 Therapeutic Development (clinical)
Posters 8-01 to 8-10
Chairs: Mitja Lainscak, Emanuele Marzetti
Poster session 3.3 Muscle Wasting & Sarcopenia
Posters 4-70 to 4-79
Chairs: Christopher Perry, Erin Talbert
Poster session 3.4 Cancer Cachexia
Posters 3-22 to 3-31
Chairs: Paige Arneson-Wissink, Egidio Del Fabbro
METROPOLITAN BALLROOM
ABSTRACT SESSION
Rapid Fire Abstracts Session 3
Chairs: Faisal Beg, Canada – Marilia Seelaender, Brazil
Using a proximity labeling approach to investigate lung-secreted proteins in an inflammatory weight loss model (2-06)
Jack Sanford , USA
Adipose tissue macrophages and IL-4 receptor signaling under hypercatabolic conditions (2-09)
Michaela Lang, Austria
MyoRep: a novel reporter system to detect early muscle atrophy in vitro and in vivo (3-10)
Rosanna Piccirillo, Italy
Territorial differences in vitamin d status and gait performance among chilean older people: a multi-regional analysis across 30 degrees of latitude (5-07)
Barbara Angel, Chile
Optimising amino acid availability in older adults: contrasting the effects of essential amino acid supplementation and a standard protein-content breakfast in a randomised crossover trial (5-08)
Theocharis Ispoglou, UK
Association between cardiovascular health metrics and self-reported walking difficulty in community-dwelling middle-aged and older adults: results from the Longevity Check-up 8+ (6-06)
Stefano Cacciatore, Italy
Associations of long-term physical activity levels with sarcopenia in older adults: the HUNT study (6-09)
Karina Tommerdal, Norway
UCN2 treatment enhanced fat mass loss while increasing muscle mass and function in preclinical models (7-08)
Pablo Vidal Souza, USA
Glycerol kinase mediated lipid cycling contributes to fat loss in cancer associated cachexia (1-01)
Pia Benedikt-Kühnast, Germany
Body composition abnormalities and their association with physical function in patients with idiopathic pulmonary fibrosis (6-07)
Felipe Machado, Belgium
16:30 – 17:45
HALL A
TBD
Session 20
Neuromuscular disorders: from acute to chronic conditions
Chairs: Marcello Maggio, Italy – Reshma Merchant, Singapore – Teresa Zimmers, USA
Neuromuscular disorders in the ICU in 2025
Joerg Schefold, Switzerland
ICU-acquired weakness: are we creating survivors or victims?
Stefan Schaller, Austria
Muscle and brain dysfunction associated with long-term mechanical ventilation
Lars Larsson, Sweden
Sarcopenia of uncertain pathogenesis: the case of systemic sclerosis (SSc)
Maurizio Muscaritoli, Italy
Discussion
HALL B
CLINICAL / TRANSLATIONAL
Session 21
Frailty, sarcopenia and cachexia in chronic liver disease: from mechanisms to therapies
Chairs: Jose Garcia, USA – Sandra Kleiner, Germany
Frailty and sarcopenia in patients with cirrhosis
TBC
Mechanisms of muscle dysfunction in MASLD
TBC
Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis
TBC
Exercise and GLP-1 agonists for MASLD-associated sarcopenia and muscle dysfunction
TBC
Discussion
18:00 – 19:00
HALL A
TRANSLATIONAL
Session 22
Data mining the electronic medical record and imaging for diagnostics in cachexia / sarcopenia
Chairs: TBC
Automated CT/L3-based body composition pipelines; AI-based opportunistic screening from routine clinical imaging
TBC
Defining cachexia staging and phenotypes using data from a large health system
Ed Reznik, USA
Wearables and digital function assessment: Advancing sarcopenia assessment with wearable and app-based technology: a scoping review
TBC
Regulatory pathway for qualifying digital biomarkers as cachexia trial endpoints
TBN
Discussion
DUPONT BALLROOM
SARCOPENIA - CLINICAL
Session 23
Nutrition and exercise for the maintenance of muscle mass
Chairs: Henning Langer, Germany – TBN
The role of protein intake and exercise during aging
TBN
Exercise versus anabolic drugs for treating sarcopenia
Phil Atherton, UK
TBD
TBN
Beyond calories: nutrients as active therapeutics in oncology care
TBC
Discussion
Sponsored symposium
19:10 – 19:55
Defining meaningful endpoints in cancer cachexia:
a patient-to-regulatory perspective
Moderator: Richard Dunne, University of Rochester, USA
Panel discussants: Carole Motycka, Fight CRC, USA – Abigail Newell, Cancer Support Community, USA – Susan Martin, Research Triangle Institute, USA
(Symposium supported by Pfizer)
Register Now!
Embrace this opportunity to redefine the field and create lasting impact in the lives of patients worldwide.
Day 3: Saturday 12 December 2026
Exploring the Intricacies of Muscle Wasting and Microbiome in Cancer Cachexia
Day three of our programme plunges us into the intricacies of muscle wasting and the microbiome’s influence in cancer cachexia. We are pleased to present a distinguished gathering of international experts, eager to share their groundbreaking research and partake in dynamic discussions.
08:00 – 09:00
HALL A
AWARD SESSION
Session 24
Young Investigators Award Session
Chairs / Judges: TBC
HALL B
TBC
Session 25
Exercise for cancer cachexia ?!
Chairs: TBC
Old muscles – can they improve?
TBC
Resistance vs. aerobic vs. combined training in cancer cachexia
TBN
Pharmacological possibilities to help patients to move more
Bo Falck Hansen, Denmark
A randomized trial of nutrition and exercise treatment in patients with pancreatic and non-small cell lung cancer (NEXTAC-TWO)
TBN
Discussion
Break
09:00 – 10:00
POSTER SESSION
west end & thomas rooms
Poster viewing 4
Poster session 4.1 Muscle Wasting & Sarcopenia
Posters 4-61 to 4-69
Chairs: Gustavo Duque, Andreas Fischer
Poster session 4.2 Cancer Cachexia
Posters 3-01 to 3-12
Chairs: Mauricio Berriel Diaz, Paola Costelli
Poster session 4.3 Cachexia
Posters 1-01 to 1-11
Chairs: Andrea Bonetto, Denis Guttridge
Poster session 4.4 Muscle Wasting & Sarcopenia
Posters 4-13 to 4-24
Chairs: Christopher Perry, Erin Talbert
10:00 – 11:15
HALL A
CLINICAL
Session 26
GLP-1RA for weight loss therapy: the issue of muscle and bone loss
Chair: Andrew Coats, Australia – Katsu Funai, USA – TBC
The problem – update 2026
TBC
The power of exercise during anti-obesity treatment
TBC
Myostatin/activin-pathway combination-therapy trial data (e.g., bimagrumab + GLP-1 agonist)
David Glass, USA
Trials landscape: muscle-sparing combination agents in active development
TBC
HALL B
BASIC
Session 27
From signals to systemic wasting: crosstalk in cancer cachexia
Chair: TBN
Impaired T cell functionality contributes to cancer cachexia
Su-Ping Ng, Germany
The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia
TBC
Tumor-secreted ADAMTSL4 activates latent TGF-β1 to drive cancer cachexia
Mauricio Berriel Diaz, Germany
The adipose tissue as an active driver of cancer and cachexia progression: depot-specific features and novel targets
Alessio Molfino, Italy
The gonad-bone-muscle axis in cancer and treatment-induced cachexia
James Carson, USA
11:30 – 12:45
HALL A
LATE BREAKING SCIENCE
Session 28
GLP-1RA for weight loss therapy: the issue of muscle and bone loss
Chair: TBC
The problem – update 2026
TBC
The power of exercise during anti-obesity treatment
TBC
Myostatin/activin-pathway combination-therapy trial data (e.g., bimagrumab + GLP-1 agonist)
TBC
Trials landscape: muscle-sparing combination agents in active development
TBC
HALL B
BASIC
Session 29
Neural inflammatory and behavioral axes in cachexia
Chair: TBC
Mechanisms of behavioral changes in cachexia
TBC
Targeting the peripheral and systemic gut-brain axes to combat cachexia
Xiling Shen, USA
Metabolism and behavior in cancer cachexia
Eileen White, USA
Sympathetic nerve mediated factors in cachexia
Aaron Grossberg, USA
Break
12:50 – 13:50
Lunch Break
Sponsored symposium
12:50 – 13:50
Defining meaningful endpoints in cancer cachexia:
a patient-to-regulatory perspective
Moderator: Richard Dunne, University of Rochester, USA
Panel discussants: Carole Motycka, Fight CRC, USA – Abigail Newell, Cancer Support Community, USA – Susan Martin, Research Triangle Institute, USA
(Symposium supported by Pfizer)
14:00-15:15
HALL A
TBC
Session 30
Emerging treatments in neuromuscular disease
Chairs: David Glass, USA – Fabio Dorigotti, Switzerland
Myostatin inhibition as a co-treatment in SMA
TBN
(s)-oxprenolol for ALS
TBC
Anti-inflammatory strategies in NMD
Agata Mossakowski, Germany
Gene-editing as a treatment for muscular dystrophies
TBC
Discussion
HALL B
TRANSLATIONAL
Session 31
Bone–muscle crosstalk in cachexia and sarcopenia
Chairs: Kamal Awad, USA – Gustavo Duque, Canada
General bone–muscle crosstalk: mechanisms and implications
Lynda Bonewald, USA
Liver-bone-muscle-cancer interactions: clinical perspectives and therapeutic opportunities
Andrea Bonetto, USA
Osteocyte mediated bone-muscle crosstalk in cancer cachexia
Fabrizio Pin, USA
Integrative musculoskeletal biomarkers: myokines, osteokines, and beyond in sarcopenia and osteoporosis
Marco Brotto, USA
Discussion
HIGHLIGHTS
15:15-16:00
HALL A
Highlights Session
Chairs: Teresa Zimmers USA – Stefan Anker, Germany – TBN
Basic Science
Aaron Grossberg, USA
Nutrition
TBN
Sarcopenia
TBN
Cancer Cachexia
TBN
Poster Award
Young Investigator Award
Farewell
